COL-3 new tetracycline derivative being studied

Written by on August 11, 2005 in tetracyclines with 0 Comments

A new anti-inflammatory compound has had some Phase 2 Clinical information published. COL-3 is a so called second generation IMPACS (Inhibitors of Multiple Proteases and Cytokines) compound. It is a tetracycline derivate, and is also designated as a Synthetic MMP (Matrix Metalloproteinsase) inhibitor.

Guy Webster, MD. PhD the lead investigator for these Phase 2 clinical trials of COL-3 says

“This is the first double-blinded, placebo-controlled clinical study evaluating COL-3’s therapeutic potential. The magnitude of the effect was greater than anticipated and the onset of action much faster, making COL-3 a promising candidate for development.”

COL-3 is being developed by Collagenex Pharmaceuticals who is also developing Oracea, another antibiotic variant targetted as a rosacea treatment.

According to Collagenex, research has shown that certain tetracyclines can be chemically modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.

COL-3 is also undergoing Phase I trials as an angiogenesis inhibitor.

Related Articles:

Read more about: tetracyclines

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.